Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

Update on Tozadenant Trial for Parkinson’s

On 11/20/17, Acorda Therapeutics, Inc. announced that it is discontinuing the tozadenant clinical trial.  They concluded that they could not be confident that weekly white blood cell count screening would sufficiently ensure patient safety.


On 11/15/17, Acorda Therapeutics, Inc. announced that several people living with Parkinson's who participated in the Phase III trial for tozadenant experienced agranulocytosis — a severe drop in the number of white blood cells which fight infection — leading to cases of sepsis and five fatalities. Participants in the trial will now have blood cell count monitoring increased from monthly to weekly.  The study has paused new enrollment in the long-term safety studies, pending further discussion with the independent Data Safety Monitoring Board (DSMB) and the United States Food and Drug Administration (FDA).

Tozadenant is an oral adenosine A2a receptor antagonist currently in Phase III development as an adjunctive treatment to levodopa in Parkinson’s disease patients to reduce OFF time.

Statement from the Parkinson’s Foundation

Our thoughts are with the family members who lost a loved one enrolled in this trial. Their participation in clinical research will ultimately help make life better for the people diagnosed with Parkinson's in the future. 

The Parkinson’s Foundation remains confident that Acorda and the FDA will investigate this rare event. Clinical trials in Parkinson’s disease — from oral therapies to surgical treatments — have had a strong safety record and they are critical in testing the safety and efficacy of investigational therapies.

In order to discover new PD therapies, we rely on brave and altruistic people, like the ones in this trial, to participate in clinical research. The Parkinson’s Foundation remains committed to supporting clinical research through our global network of Centers of Excellence and Parkinson’s Advocates in Research.

If you would like more information about the benefits and risks of clinical trial participation, learn more here.  If you have questions or concerns, please call our toll-free Helpline at 1-800-4PD-INFO (473-4636).

Thursday, November 16, 2017
Parkinson’s Foundation to Host 60th Anniversary Gala on Wednesday, May 31
Monday, March 20, 2017

The 60th Anniversary Gala to benefit Parkinson’s Foundation will take place Wednesday, May 31, 2017 in the Garden Terrace Room at the New York Botanical Garden in the Bronx, NY.  The Gala marks the 60th Anniversary of both the Parkinson ’s Disease Foundation (PDF) and the National Parkinson Foundation (NPF), the legacy organizations of the Parkinson’s Foundation and recognizes their

Parkinson’s Foundation Mourns the Passing of Lewis P. Rowland, M.D.
Friday, March 17, 2017

The Parkinson’s Foundation mourns the loss of Lewis P. “Bud” Rowland, M.D., Emeritus member of its Board of Directors and longtime champion of its work to end Parkinson’s. Dr. Rowland, who also served as President of the Parkinson’s Disease Foundation (PDF) division of the Parkinson’s Foundation for many years, passed away on March 16.

Local Residents Raise Nearly $40,000 for Parkinson’s Research at Scotch & Sangria Event in Closter, NJ
Thursday, March 9, 2017

Proceeds From Fourth Annual Helping Hours Event Benefit Parkinson’s Foundation

Advocates Guide $16 Million in US Department of Defense Parkinson’s Research Funding for Second Straight Year
Tuesday, March 7, 2017

Recently, four Parkinson’s Foundation Research Advocates helped guide $16 million in government funding for Parkinson’s disease (PD) research. This is the second straight year in which our Research Advocates have served as consumer reviewers for research funded by the US Department of Defense (DoD). The group included:

Parkinson’s Foundation Receives Award to Develop National Recommendations to Improve Care for Women with Parkinson’s
Tuesday, February 28, 2017

NEW YORK CITY & MIAMI — The Parkinson's Foundationhas received a $250,000 award to develop new patient-centered recommendations to improve the health of women living with Parkinson’s disease.

Parkinson’s Foundation Invests $500,000 in Community-Driven Clinical Research To Ease Cognition, Sleep and Fatigue in Parkinson’s
Monday, February 27, 2017

Five New Awards Address Unmet Needs

New York, NY and Miami, FL — The Parkinson’s Foundation has awarded $500,000 for translational research grants to address critical unmet needs in Parkinson’s disease.  The investments jumpstart practical solutions to ease difficulties related to cognition, fatigue and sleep, all of which are debilitating yet under-recognized symptoms in Parkinson’s.

The Parkinson's Foundation’s Moving Day® Walks Fund Local Parkinson’s Programs in 2017
Monday, February 13, 2017

$13.7 million dollars raised over five years
 

Young New Yorkers for the Fight Against Parkinson’s Committee and the Parkinson’s Foundation Celebrate the 10th Anniversary of Celebrate Spring New York Wednesday, April 5, 2017
Friday, February 10, 2017

The 10th Anniversary of Celebrate Spring New York will take place on Wednesday, April 5, 2017 at Lavo located at 39 East 58th Street between Madison and Park Avenues.  The event is hosted by the Young New Yorkers for the Fight Against Parkinson’s and the Parkinson’s Disease Foundation (PDF), a division of the Parkinson’s Foundation.

Parkinson’s Foundation Designates NewYork-Presbyterian/Columbia, Rush University Medical Centers as Parkinson’s Care ‘Centers of Excellence’
Monday, February 6, 2017

As foundation continues to invest in programs to improve the lives of Parkinson’s patients, designation of new Centers of Excellence further expand expert care network
 

Local Residents to Host Scotch & Sangria for Parkinson’s Research at Sear House in Closter, NJ, on Thursday, March 2
Monday, January 30, 2017

Proceeds From Fourth Annual Helping Hours Event Benefit Parkinson’s Foundation

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.